Question 1a
|
Does your trust treat advanced breast cancer ?
|
Yes
|
Question 1b
|
If none, where are your patients referred?
|
N/A
|
|
|
|
Question 2
|
In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;
|
This information is not recorded on the patient administration system and would take longer than 18 hours to find as it would require a manual search of patient records. Therefore, under section 12 of the Freedom of Information act, we are not obliged to provide this.
|
|
HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
|
|
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]
|
|
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
|
|
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease
|
|
Not Known
|
|
|
|
Question 3
|
In the past 3 months, how many breast cancer patients were treated with:
|
Period 01/06/19 to 31/08/19
|
|
Abemaciclib (Verzenios) + aromatase inhibitor *
|
1
|
|
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
|
5
|
|
Alpelisib (Piqray) + Fulvestrant (Faslodex)
|
0
|
|
Atezolizumab (Tecentriq)**
|
11
|
|
Bevacizumab (Avastin)
|
9
|
|
Eribulin (Halaven)
|
6
|
|
Everolimus (Afinitor) + Exemestane
|
0
|
|
Fulvestrant (Faslodex) as a single agent
|
9 * only compared to drugs in request
|
|
Gemcitabine + paclitaxel
|
9
|
|
Lapatinib (Tyverb)
|
0
|
|
Neratinib (Nerlynx)
|
0
|
|
Olaparib (Lynparza)
|
3
|
|
Palbociclib (Ibrance) + aromatase inhibitor*
|
5
|
|
Pertuzumab (Perjeta) + trastuzumab + docetaxel
|
0
|
|
Ribociclib (Kisqali) + aromatase inhibitor*
|
0
|
|
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
|
0
|
|
Talazoparib (Talzenna)
|
0
|
|
Trastuzumab + paclitaxel
|
8
|
|
Trastuzumab as a single agent
|
58* only compared to drugs in request
|
|
Trastuzumab emtansine (Kadcyla)
|
5
|
|
Other active systemic anti-cancer therapy **
|
Not available for indications
|
|
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
|
|
|
**eg. docetaxel, vinorelbine or capecitabine as a single agent
|
|